We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Cotinine Assay Rapidly Confirms Nonsmoking Status

By LabMedica International staff writers
Posted on 13 Jan 2014
A novel, rapid and user-friendly diagnostic test provides confirmation that an individual has stopped smoking tobacco cigarettes.

In addition to being healthier, not smoking can significantly reduce the cost of health insurance. More...
However, until recently it has not been easy to prove diagnostically that an individual was a non-smoker.

Toward this end, the British biotech company GFC Diagnostics (Bicester, United Kingdom) has introduced the Saliva SmokeScreen test. The test detects cotinine, a breakdown product of nicotine. Cotinine has an in vivo half-life of approximately 20 hours, and is typically detectable for several days (up to one week) after the use of tobacco. The level of cotinine in the blood is proportionate to the amount of exposure to tobacco smoke, so it is a valuable indicator of tobacco smoke exposure. The newly improved Saliva SmokeScreen assay is more sensitive and specific than its previous version, being reported at 90% and 98% respectively, with an accuracy of 94%.

To test for nicotine exposure the user places the test swab in the mouth to absorb 1.5 mL of saliva. The swab is removed from the mouth, placed inside the plastic collector, and pushed against the grid half way down. This procedure squeezes the saliva into the bottom of the collector. The presence of cotinine causes a color change that is visible after one minute. The optimal time to read the result is six minutes. If read before five minutes, the result will be positive, but less than the correct result. After six minutes, it will be more than the true result.

The Saliva SmokeScreen test has been certified as a tool in a British health insurer's program to verify nonsmoking in their policy holders, so they can qualify for its unique nonsmoker cash back reward. Dr. Graham Cope, technical director at GFC Diagnostics and an honorary senior research fellow at the University of Birmingham (United Kingdom), said, "Smoking is an important risk factor for many chronic diseases, such as respiratory diseases, cardiovascular disease, and diabetes. It also causes blood pressure to rise and is linked with high cholesterol levels. We are pleased the SmokeScreen test has been chosen as the means to monitor smoking in this program."

Related Links:

GFC Diagnostics
University of Birmingham



New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.